Seizert Capital Partners LLC Lowers Position in Johnson & Johnson (NYSE:JNJ)

Seizert Capital Partners LLC lessened its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 1.3% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 259,245 shares of the company’s stock after selling 3,525 shares during the quarter. Johnson & Johnson makes up about 2.1% of Seizert Capital Partners LLC’s investment portfolio, making the stock its 14th largest position. Seizert Capital Partners LLC’s holdings in Johnson & Johnson were worth $45,946,000 as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. Norges Bank purchased a new stake in Johnson & Johnson during the fourth quarter valued at $4,172,929,000. BlackRock Inc. raised its stake in Johnson & Johnson by 2.6% during the fourth quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock valued at $34,217,654,000 after purchasing an additional 4,982,885 shares in the last quarter. GQG Partners LLC raised its stake in Johnson & Johnson by 1,109.4% during the fourth quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock valued at $676,375,000 after purchasing an additional 3,627,424 shares in the last quarter. State Street Corp increased its position in Johnson & Johnson by 1.8% during the fourth quarter. State Street Corp now owns 144,677,639 shares of the company’s stock valued at $24,750,004,000 after acquiring an additional 2,492,359 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Johnson & Johnson by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock valued at $7,576,867,000 after acquiring an additional 1,084,834 shares during the last quarter. Hedge funds and other institutional investors own 68.78% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on JNJ. Wells Fargo & Company boosted their price objective on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research report on Wednesday, July 13th. The Goldman Sachs Group boosted their price objective on shares of Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research report on Tuesday, April 12th. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research report on Friday, July 8th. UBS Group cut their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Finally, SVB Leerink cut their price target on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Stock Down 0.3 %

Shares of Johnson & Johnson stock opened at $173.91 on Tuesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. The stock has a market cap of $457.63 billion, a price-to-earnings ratio of 25.31, a PEG ratio of 3.32 and a beta of 0.59. The firm’s 50-day moving average is $175.84 and its two-hundred day moving average is $174.50. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. The firm had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The company’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period last year, the firm earned $2.48 earnings per share. As a group, research analysts expect that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.60%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.

Insider Buying and Selling

In related news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,785,140. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,785,140. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.